Accelerating discovery
from tissue to therapy.

The challenge.

Biomarker discovery is central to advancing precision medicine, but most research depends on invasive blood sampling or static lab tests. These limitations reduce sampling frequency, overlook localized biological signals, and make real-world longitudinal data difficult to obtain. Critical biomarkers can remain undetected, or misunderstood, without a more accessible and dynamic sampling medium.

The opportunity.

KIFFIK Lab offers scalable, repeatable access to interstitial fluid (ISF), providing researchers with a unique window into tissue-adjacent biology. By enabling real-time collection of molecular data, without blood draws, KIFFIK transforms how biomarkers are discovered, validated, and monitored. Our platform supports translational research across therapeutic areas with minimal burden on participants.

Clinical application:

  • Early-phase biomarker discovery in immune, metabolic, and oncologic pathways

  • Pharmacodynamic and pharmacokinetic profiling in clinical trials

  • Companion diagnostic development in personalized medicine

  • Population-scale studies using decentralized, non-invasive sampling

Potential biomoarkers:

  • IL-6, CRP (inflammatory signaling)

  • Adiponectin, leptin (metabolic regulation)

  • VEGF, IL-8 (oncogenic pathways)

  • S100B, GFAP (neuroinflammatory injury)

Every breakthrough begins with better data. KIFFIK gives researchers a new lens on human biology, continuously, painlessly, and in real time.